[Click eStock] "Appclon, Expected Technology Export of CAR-T Therapeutics"

Daishin Securities stated on the 11th that Appclon is expected to announce the interim results of the Phase 2 clinical trial for its main pipeline (AT101) in the second half of this year, anticipating an increased possibility of technology export.

Researcher Han Song-hyeop from Daishin Securities explained, "AT101 showed excellent results in Phase 1 clinical trials," and "It was confirmed that the therapeutic effect is maintained for a long period." He added, "The Phase 2 clinical trial is currently underway in Korea," and "It is expected to be launched in the domestic market by 2026."

He analyzed, "Annual sales of 25 to 30 billion KRW can be expected," and "They have established their own GMP facility and secured key patents related to CAR-T manufacturing technology." He also noted, "Approval for investigator-initiated clinical trials has been obtained from the Korean Ministry of Food and Drug Safety," and "If meaningful results are announced, the possibility of technology export will increase."

The researcher stated, "They have secured a revenue base through various pipelines," and "AC101 has demonstrated excellent efficacy in Phase 2 clinical trials and is about to enter Phase 3." He added, "It is a biotech company with competitiveness based on differentiated CAR-T technology and production infrastructure," and "The company's value is expected to rise along with the rapid growth of the CAR-T market."

This content was produced with the assistance of AI translation services.